Acorda Therapeutics (ACOR) Reports Q4 Loss of $0.67
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
March 9, 2022 4:01 PM ESTAMPYRA® (dalfampridine) Extended Release Tablets, 10 mg 2021 net revenue of $84.6 million AMPYRA Q4 2021 net revenue of $22.5 million INBRIJA® (levodopa inhalation powder) 2021 net revenue of $29.6 million; 22% increase over 2020 INBRIJA Q4 2021 net revenue of $10.4 million; 12% increase over Q4 2020 Total 2022 non-GAAP operating expense expected to be $110-$120 million1 AMPYRA 2022 net revenue expected to be $68 - $78 million
ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the fourth quarter and full year ended December 31, 2021.
In 2021, we... More
